Allergen‐Specific IgE is a Stronger Predictor of Remission Following Peanut Oral Immunotherapy Than Age in Children Aged 1–10 Years
Allergy · 2025
DOI: 10.1111/all.16451 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Allergy, 2025. Verfasst von Sarah E Ashley und 8 weiteren Autor:innen. Beteiligte Einrichtung: Murdoch Children's Research Institute, Parkville, Australia. Hauptthemen laut MEDLINE: Peanut Hypersensitivity, Allergens, Desensitization, Immunologic, Immunoglobulin E. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Remission is the desired outcome following OIT as it allows individuals to discontinue treatment and eat the allergen freely. Early initiation of OIT in infants and toddlers has been embraced as an approach to increase the likelihood of remission. However, there is no high‐quality evidence supporting younger age as an independent factor driving remission; available studies are limited by small samples of younger subjects and lack of adjustment for confounding covariates, particularly peanut‐specific IgE (sIgE) levels which is closely correlated with age.
Methods
This study examined relationships between peanut sIgE and age at baseline and remission, in children aged 1–10 who completed 18 months of OIT in the PPOIT‐003 RCT ( n = 162). Remission was defined as absence of clinical reactivity to peanut after 8 weeks of allergen avoidance/treatment discontinuation. Age and sIgE were examined as continuous variables in univariate and multivariate regression models.
Results
Higher peanut sIgE was consistently predictive of lower likelihood of remission, independent of age. In contrast, there was no independent association between age and remission after adjusting for baseline sIgE (OR 0.94 [0.79–1.12], p = 0.5).
Conclusions
Findings do not support age as an independent predictor of remission following OIT. Additional studies examining safety and efficacy of OIT in infants and younger children are urgently needed, ahead of widespread adoption of early intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Murdoch Children's Research Institute, Parkville, Australia.
- The University of Melbourne, Parkville, Australia.
- The Royal Children's Hospital Melbourne, Parkville, Australia.
- Monash University Parkville Campus, Parkville, Australia.
- Monash Children's Hospital, Clayton, Australia.
- Telethon Kids Institute, Nedlands, Australia.
ORCID-Profile: Sarah E Ashley, Paxton Loke
Zitieren
APA
Ashley, S. E., Lloyd, M., Loke, P., Orsini, F., Lozinsky, A. C., O'Sullivan, M. D., Quinn, P., Gold, M., & Tang, M. L. K. (2025). Allergen‐Specific IgE is a Stronger Predictor of Remission Following Peanut Oral Immunotherapy Than Age in Children Aged 1–10 Years. Allergy. https://doi.org/10.1111/all.16451
Vancouver
Ashley SE, Lloyd M, Loke P, Orsini F, Lozinsky AC, O'Sullivan MD, et al. Allergen‐Specific IgE is a Stronger Predictor of Remission Following Peanut Oral Immunotherapy Than Age in Children Aged 1–10 Years. Allergy. 2025. doi:10.1111/all.16451
BibTeX
@article{Ashley2025,
author = {Ashley, Sarah E and Lloyd, Melanie and Loke, Paxton and Orsini, Francesca and Lozinsky, Adriana C and O'Sullivan, Michael D and Quinn, Patrick and Gold, Michael and Tang, Mimi L K},
title = {Allergen‐Specific IgE is a Stronger Predictor of Remission Following Peanut Oral Immunotherapy Than Age in Children Aged 1–10 Years},
journal = {Allergy},
year = {2025},
doi = {10.1111/all.16451}
}
EUVIMED